Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Mid-Afternoon Market Update: Crude Oil Down Over 2.5%; American Express Shares Gain On Earnings Beat

Benzinga.com  October 20, 2016

18 Biggest Mid-Day Losers For Thursday

Benzinga.com  October 20, 2016

Rigel Pharma Shares Suffering After Phase 3 Study Failure

Benzinga.com  October 20, 2016

Mid-Morning Market Update: Markets Mostly Higher; Verizon Posts Mixed Q3 Results

Benzinga.com  October 20, 2016

Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP

PR Newswire October 20, 2016

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 10, 2016

Rigel Expands Leadership Team in Research and Business Development

PR Newswire October 7, 2016

Watch These 5 Huge Call Purchases In Thursday Trade

Benzinga.com  September 29, 2016

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  August 31, 2016

12 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  August 31, 2016

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 30, 2016

Mid-Day Market Update: Abercrombie & Fitch Drops On Wider Loss; Rigel Pharmaceuticals Shares Surge

Benzinga.com  August 30, 2016

Market Movers & Headline Makers On Tuesday

PR Newswire August 30, 2016

Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Benzinga.com  August 30, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  August 30, 2016

Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

PR Newswire August 30, 2016

Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016

PR Newswire August 29, 2016

Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism

Benzinga.com  July 13, 2016

Rigel to Present at Jefferies 2016 Healthcare Conference

PR Newswire June 2, 2016

Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting

PR Newswire May 5, 2016